Staar Surg Stock Price, News & Analysis

STAAR (NASDAQ: STAA) highlighted independent industry analyst commentary endorsing its proposed cash merger with Alcon at $28 per share. Analysts cite a ~59% premium to STAAR’s 90‑day VWAP, an implied total equity value of ~$1.5 billion and multiples ranging from ~4.7x FY26 sales to ~6x 2025 sales. STAAR warned of sustained standalone risks driven by severe China weakness (China revenue fell to $5.3M, -92% Y/Y) and channel inventory issues. The STAAR Board unanimously recommends voting “FOR” the merger at a special meeting on October 23, 2025.

STAAR Surgical (NASDAQ: STAA) urged stockholders to vote FOR the proposed merger with Alcon, saying the deal delivers $28 per share in cash and a 59% premium to STAAR's 90‑day VWAP (and a 51% premium to the Aug 4, 2025 close). The Board unanimously recommended the merger and says the process was thorough, rejecting Broadwood Partners’ criticisms as flawed and misleading.

STAAR highlighted material headwinds: net sales have declined since 2023, China represented 51% of net sales, Q2 2025 showed a $16.8M net loss, and management projects 10% annual net‑sales growth (2026–2030). Closing is expected in ~6–12 months, subject to regulatory and shareholder approval.

Broadwood Partners (holder of approx. 27.5% of STAAR common stock) published an 81-page presentation on October 3, 2025 urging STAAR stockholders (NASDAQ: STAA) to vote "AGAINST" the proposed acquisition by an affiliate of Alcon (NYSE: ALC). Broadwood says the deal, announced August 5, 2025, comes "at the wrong time, after the wrong process, and at the wrong price" and contends the board failed to run a responsible sale process and agreed to a price that "significantly undervalues" STAAR. The presentation is posted at LetSTAARShine.com.

STAAR Surgical (NASDAQ: STAA) and Alcon (SIX/NYSE: ALC) announced the expiration of the Hart-Scott-Rodino waiting period for Alcon's planned acquisition of STAAR. The $1.5 billion all-cash transaction values STAAR at $28 per share, representing a 59% premium to STAAR's 90-day volume weighted average price.

The merger will combine Alcon's eye care leadership with STAAR's Implantable Collamer® Lens technology, expanding treatment options across the full spectrum of myopia. The transaction is expected to close within 6-12 months of the August 5, 2025 announcement, pending stockholder approval at the October 23 Special Meeting and regulatory clearances.

STAAR Surgical (NASDAQ: STAA) has published a presentation defending its pending merger with Alcon (SIX/NYSE: ALC) at $28.00 per share in cash. The deal represents a 59% premium to STAAR's 90-day volume weighted average price before announcement. The company's second-largest stockholder, Soleus Capital (6% ownership), has expressed support for the merger.

STAAR faces significant challenges, including declining China sales (approximately 50% of consolidated net sales), intensifying competition, and limited product offerings. The Board conducted extensive strategic reviews, meeting over 20 times in the first eight months of 2025. Despite a 45-day "window shop" period, no competing acquisition proposals emerged.

The company strongly refutes claims by Broadwood Partners against the merger, emphasizing that STAAR's stock traded at $18.49 per share before the announcement and warning of potential downward pressure if the merger fails.

Broadwood Partners, holding approximately 27.5% of STAAR Surgical Company (NASDAQ: STAA) shares, has filed a definitive proxy statement urging stockholders to vote AGAINST the proposed $28 per share acquisition by Alcon (NYSE: ALC).

Broadwood criticizes the deal citing three main issues: poor timing during STAAR's temporary market challenges and imminent turnaround, a flawed process that excluded other potential buyers, and significant conflicts of interest involving board members and management. The firm highlights that Alcon previously proposed $62 per share less than a year ago, representing a 55% decrease in the current offer.

The investment firm emphasizes STAAR's strong fundamentals, including $200 million in cash, no debt, leading technology, and promising growth prospects. Another major stockholder, Yunqi Capital Ltd. (5.1% ownership), also opposes the transaction.

STAAR Surgical (NASDAQ: STAA) announced the expiration of its 45-day "window shop" period related to its pending merger with Alcon (SIX/NYSE: ALC), with no competing acquisition proposals received. The merger agreement offers $28.00 per share in all-cash consideration, representing a 51% premium to STAAR's closing price on August 4, 2025.

Despite claims from Broadwood Partners about potential alternative buyers, no competing proposals emerged since July 2024. The deal includes a 1% termination fee during the window shop period, increasing to 3% for superior proposals after September 19, 2025. The Board unanimously supports the Alcon merger, citing it as the best path forward for stockholders amid continuing business challenges.

Yunqi Capital, a 5.1% stakeholder in STAAR Surgical Company (NASDAQ:STAA), has announced its opposition to STAAR's proposed sale to Alcon (SIX/NYSE:ALC) at $28 per share. As STAAR's sixth-largest shareholder with 2,500,061 shares, Yunqi Capital argues that the deal significantly undervalues the company.

The Hong Kong-based investment firm criticizes the Board's decision on three main grounds: (1) failure to conduct a thorough sales process by engaging only with Alcon, (2) an overly pessimistic view of China's market prospects, and (3) inadequate deal valuation, noting the $28 offer represents a 49% discount from Alcon's original October 2024 offer of $55 per share.

Yunqi Capital intends to vote against the merger and urges other shareholders to do the same, aligning with Broadwood Partners (27.4% stockholder) in opposing the transaction.